HANA EL SAHLY to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications HANA EL SAHLY has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.333
-
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Ann Intern Med. 2021 08; 174(8):1118-1125.
Score: 0.172
-
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
Score: 0.060
-
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. J Infect Dis. 2024 Dec 16; 230(6):1384-1389.
Score: 0.056
-
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
Score: 0.045